Cargando…
The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) have become one important therapeutic strategy for advanced non‐small‐cell lung cancer (NSCLC). It remains imperative to identify reliable and convenient biomarkers to predict both the efficacy and toxicity of immunotherapy, and tumor‐associated autoan...
Autores principales: | Zhao, Jing, Wu, Yang, Yue, Yuan, Chen, Minjiang, Xu, Yan, Liu, Xiangning, Liu, Xiaoyan, Gao, Xiaoxing, Wang, Hanping, Si, Xiaoyan, Zhong, Wei, Zhang, Xiaotong, Zhang, Li, Wang, Mengzhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925345/ https://www.ncbi.nlm.nih.gov/pubmed/36594104 http://dx.doi.org/10.1111/1759-7714.14772 |
Ejemplares similares
-
Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022) -
Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022) -
Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022) -
Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case–control study
por: Si, Xiaoyan, et al.
Publicado: (2023) -
Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)